Fresh off today’s positive advisory committee vote backing tazemetostat for epithelioid sarcoma, Epizyme (NASDAQ:EPZM) files another marketing application with the FDA for the EZH2 inhibitor.
The new indication is relapsed/refractory follicular lymphoma, with or without EZH2 mutations, in patients who have received at least two prior lines of therapy.
The company is seeking accelerated approval of the filing.
Shares up 2% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.